Researchers from Chinese medical institutions conducted a comprehensive review examining how inflammation functions as a central regulator of immunotherapy efficacy in head and neck squamous cell carcinoma (HNSCC). The study analyzed the complex interplay between chronic inflammatory signals, immune cell behavior, and tumor biology to explain immunotherapy response variability. Key findings revealed that inflammatory pressure reprograms critical immune cells—including macrophages, regulatory T cells, exhausted CD8+ T cells, and dendritic cell subsets—transforming them from tumor-suppressing sentinels into promoters of tumor growth and invasion. The researchers identified inflammation-driven signaling pathways including NF-κB/STAT3, IL-6/TNFα, TGF-β, and PI3K-4EBP1-SOX2 as orchestrators of immunotherapy response. They catalogued biomarkers such as PD-L1, CD163/CD68 ratios, LAMP3, and CD44 isoforms that provide enhanced patient stratification when analyzed at single-cell and spatial resolution. This framework is significant because it demonstrates how understanding inflammation-induced immune cell plasticity and associated molecular pathways enables better prediction of checkpoint blockade success or failure, potentially improving treatment outcomes for HNSCC patients.

In situ cancer vaccination, also known as intratumoral immunotherapy, represents a promising approach that transforms tumors into personalized vaccine platforms by leveraging the tumor itself as an antigen source. Unlike conventional tumor-associated antigen or personalized neoantigen vaccines requiring predefined targets and complex manufacturing, this strategy exposes the tumor's complete antigenic repertoire—including tumor-associated antigens, neoantigens, post-translationally modified epitopes, and viral antigens—within their native context. This broad exposure triggers robust polyclonal cytotoxic T-cell responses and epitope spreading while reducing immune escape from tumor heterogeneity. The approach coordinates multiple immune mechanisms through programmed cell death pathways including immunogenic apoptosis, pyroptosis, necroptosis, and ferroptosis, which release tumor antigens and danger-associated molecular patterns promoting dendritic-cell activation and durable T-cell responses. Incorporation of potent adjuvants and advanced delivery platforms enhances immune activation and remodels the immunosuppressive tumor microenvironment. Despite advantages, clinical translation faces challenges including inconsistent immunogenic cell death induction, suboptimal intratumoral therapeutic retention, and T-cell infiltration barriers. Recent advances in nanomedicine delivery systems, microenvironmental modulation, and combinatorial strategies with immune checkpoint blockade are addressing these limitations, positioning in situ cancer vaccination as a broadly applicable, patient-tailored immunotherapy capable of generating durable systemic antitumor immunity.

The NOA16 trial evaluated the safety and immunogenicity of IDH1-vac, a peptide vaccine targeting the IDH1-R132H mutation found in most astrocytomas, in 33 patients with newly diagnosed grade III and IV IDH1-mutant astrocytomas. The vaccine was integrated into standard treatment protocols. Long-term follow-up data reveal impressive clinical outcomes, with 8-year progression-free and overall survival rates of 42 and 66 percent respectively. Grade IV astrocytoma patients achieved a median overall survival of 106.1 months, substantially exceeding the published range of 31.6 to 56.4 months for this population. Sustained antibody responses to IDH1-R132H correlated with favorable long-term outcomes. Notably, IDH1-vac-induced T cell responses were detected in brain lesions associated with pseudoprogression, while absent in patients experiencing early progressive disease. These compelling long-term results support advancing IDH1-vac into a randomized phase 2 trial for newly diagnosed IDH-mutant astrocytomas, representing a promising immunotherapeutic approach for this challenging brain tumor population.

This article reviews significant glioblastoma research developments from mid-2026, the thirty-seventh installment in a bimonual series tracking potential treatments for this aggressive brain tumor. A pivotal finding centers on the BT008NA study, sponsored by Insightec and published in Lancet Oncology, which evaluated focused ultrasound combined with microbubbles to transiently open the blood-brain barrier—a major obstacle preventing chemotherapy from reaching tumors. In this international phase 1/2 trial, patients receiving monthly focused-ultrasound treatments with temozolomide achieved median progression-free survival of nearly 14 months and overall survival exceeding 30 months, compared to 8 and 19 months respectively in standard-treatment controls. Though the technique did not directly quantify drug delivery to tumors, results demonstrated feasibility, safety, and efficacy, positioning ultrasound-mediated barrier opening as a platform potentially extensible to immunotherapies and other agents, with ongoing studies combining the approach with bispecific antibodies and bevacizumab. Additionally, a phase 1 gene therapy study published in Nature Medicine investigated interferon-α delivered directly to the tumor microenvironment, targeting glioblastoma's immunologically "cold" characteristics and myeloid-driven immunosuppression.

Glioblastoma remains a highly lethal primary brain tumor with poor prognosis despite aggressive multimodal treatment including surgery, radiotherapy, and chemotherapy. The primary obstacle to therapeutic success is an intensely immunosuppressive tumor microenvironment characterized by immune exclusion, defective antigen presentation, and profound T-cell dysfunction. Multiple cellular components, including tumor-associated macrophages, microglia, myeloid-derived suppressor cells, and regulatory T cells, collectively establish this suppressive niche through cytokine signaling, metabolic restriction, and checkpoint ligand expression. Key molecular pathways including TGF-β/SMAD, IL-10/STAT3, and hypoxia-HIF-1α signaling converge to prevent effective antitumor immunity. This review examines the cellular and molecular mechanisms underlying immune suppression in glioblastoma and evaluates emerging therapeutic approaches such as myeloid reprogramming, checkpoint blockade combinations, and metabolic interventions designed to convert immune-excluded tumors into immune-responsive disease.

Researchers have developed a novel ultrasound-triggered chemotherapy approach that significantly extends survival in glioblastoma, an aggressive brain cancer. Led by Joshua Antonio Whiting and colleagues, this study demonstrates the potential of combining targeted drug delivery with ultrasound activation in a genetically engineered tumor model. The innovation addresses a critical challenge in glioblastoma treatment by enabling localized chemotherapy release directly at the tumor site, potentially reducing systemic toxicity while improving therapeutic efficacy. This advancement represents a promising therapeutic strategy for enhancing survival outcomes in this notoriously difficult-to-treat malignancy.

Glioblastoma multiforme (GBM) represents one of the most aggressive brain cancers, with annual incidence rates of 3–5 per 100,000 population globally. Current standard treatment protocols combining surgery, radiation, and chemotherapy yield disappointing outcomes, with median overall survival of only 10–15 months and 5-year survival rates below 10 percent. Immunotherapy emerges as a promising therapeutic avenue, leveraging the patient's immune system to selectively target malignant cells while preserving healthy tissue. This innovative approach seeks to reprogram immune cells to distinguish between cancerous and normal brain tissue, potentially circumventing conventional treatment limitations and reducing relapse incidence. Given GBM's poor prognosis, immunological interventions represent a critical advancement in improving patient outcomes and survival prospects.

Recent clinical trials show that CAR T cell therapies can initially blunt tumor growth in patients with glioblastoma (GBM). However, therapeutic efficacy remains limited by the immunosuppressive tumor microenvironment and restricted immune cell trafficking across the blood-brain barrier (BBB). To counteract these challenges, we have utilized the oncolytic adenovirus (OV) Ad5-Δ24-RGD as a platform to overexpress a bispecific T cell engager (BiTE) targeting both CD3 on T cells and the GBM-specific tumor associated antigen IL-13Rα2. We first demonstrated that OV-BiTE can significantly increase the recruitment of T cells to GBM, both in vitro and in vivo.

Glioblastoma (GBM) represents one of the prototypical immune-cold tumors, characterized by profound immune suppression, T-cell exclusion, low neoantigen burden, and a highly immunosuppressive myeloid-dominant tumor microenvironment (TME). Despite advances in immunotherapy, including immune checkpoint blockade (ICB), CAR-T cells, and cancer vaccines, clinical benefits remain limited. This review synthesizes emerging evidence on multi-modal strategies aimed at reprogramming the cold TME into an immunologically active state. We highlight innate immune agonists, oncolytic virotherapy, precision nanomedicine, metabolic modulation, and radiotherapy-immune synergies. We further propose an integrated framework combining spatial immunomics, targeted delivery technology, and TME-specific engineering to overcome the therapeutic bottlenecks of GBM.

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of liquid blood cancers by engineering a patient’s own immune cells to destroy malignant targets, replicating this success in solid brain tumors has repeatedly failed due to the brain’s immunosuppressive microenvironment.

Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells have emerged as a promising modern immunotherapeutic strategy, offering advantages over CAR-T cell therapy due to their innate cytotoxicity, safety profile, and potential for scalable, off-the-shelf allogeneic manufacturing. CAR-NK cells can be generated from multiple sources, with recent clinical studies demonstrating notable efficacy and lack of severe toxicity in hematologic malignancies. Nevertheless, the translation of this success to solid tumors is hampered by limited NK cell persistence, trafficking and infiltration challenges, and the hostile, immunosuppressive tumor microenvironment. This review provides a comprehensive synthesis of recent advances and innovations in CAR-NK cell engineering, addresses challenges posed by the solid tumor microenvironment, and highlights both rational preclinical strategies and early-phase clinical trials in solid tumors, underscoring the evolving and transformative promise of CAR-NK therapy for a broader range of human cancers in the near future.

This research examines strategies for reprogramming dendritic cells to counteract tumor-induced immune suppression. Dendritic cells, critical regulators of immune responses, often become dysfunctional within tumor microenvironments, limiting immunotherapy effectiveness. The article explores novel mechanisms through which tumors impair dendritic cell function and presents innovative approaches to restore their antigen-presenting capacity and T-cell activation potential. By understanding and reversing tumor-mediated dysfunction, enhanced dendritic cell reprogramming could significantly improve cancer immunotherapy outcomes, offering promising therapeutic avenues for overcoming immune evasion in oncology.

Glioblastoma remains the most lethal primary central nervous system malignancy with poor prognosis despite conventional treatments. Oncolytic viruses represent an innovative immunotherapy approach that simultaneously destroys tumors and activates antitumor immune responses. However, their clinical efficacy is limited by delivery challenges, including the blood-brain barrier and complex tumor microenvironment. Hydrogels, constructed from natural and synthetic polymers, offer a promising solution by enabling sustained therapeutic payload delivery and facilitating combination treatments with immune checkpoint inhibitors. This review examines advances and obstacles in oncolytic virus therapy, explores hydrogel-mediated delivery mechanisms, and discusses opportunities for synergistic hydrogel-virus-immune adjuvant combinations in treating glioblastoma and other high-grade brain tumors.

The GT-20 trial investigates personalized neoantigen vaccination as a novel immunotherapy approach for glioblastoma, particularly in MGMT-unmethylated patients where conventional treatments have proven ineffective. Led by Elizabeth A. R. Garfinkle and colleagues, this phase 1 study evaluated GNOS-PV01, a customized DNA vaccine targeting up to 40 patient-specific tumor mutations identified through multi-regional sampling and sequencing. By incorporating a broader range of neoantigens than previous platforms, the vaccine aims to enhance immune recognition while minimizing escape mechanisms. The study's primary objective assessed the safety and feasibility of manufacturing and administering such complex personalized vaccines, representing a promising shift toward individualized cancer immunotherapy strategies for this challenging malignancy.

Although FDA-approved drugs are effective, they cause systemic toxicity for their non-specific distribution in healthy organs and tissues, and for this reason, there is urgent need to use biomaterials to develop drug delivery systems to mitigate these side effects. In this context, biomaterials-based delivery systems offer clear advantages by enhancing drug bioavailability, solubility, stability, safety, and controlled release, thereby potentially enhancing therapeutic efficacy while minimizing off-target effects. Despite these advances, the field remains largely preclinical, and a gap persists between promising experimental outcomes and successful clinical implementation. Natural biomaterials, such as hyaluronic acid, alginate, gelatin, and collagen provide intrinsic biocompatibility and bioactivity, yet often suffer from batch variability and limited mechanical tunability. In contrast, synthetic polymers offer greater control over physicochemical properties and scalability but may raise concerns regarding long-term biocompatibility and degradation profiles. Moreover, a limited number of biomaterial-based systems successfully progress to clinical trials, often due to challenges related to their ability to overcome biological barriers such as BBB, stability, large-scale production, administration routes, and in vivo circulation.

This article explores a novel paradigm for glioblastoma immunotherapy centered on meningeal immunity and "interstitial" therapeutic approaches. Glioblastoma, the most aggressive primary brain tumor in adults, presents substantial immunotherapy challenges including the blood-brain barrier, immunosuppressive tumor microenvironment, and limited immune cell infiltration. Recent discoveries of the dural lymphatic system and tissue-resident border-associated macrophages have revealed new opportunities. The proposed "interstitial" immunotherapy strategy shifts focus from the tumor interior to its border regions, leveraging meningeal immune advantages. This review comprehensively examines current GBM immunotherapy limitations, meningeal immunity mechanisms, border-associated macrophage functions, and the theoretical and clinical potential of this innovative approach to enhance therapeutic outcomes and survival.

Between July 2025 and June 2026, numerous clinical trials opened for adult and pediatric patients with primary brain tumors across the United States. This report highlights recently launched studies offering new therapeutic approaches and diagnostic innovations. Notable trials include a phase IIb investigation combining ultrasound sonodynamic therapy with gene therapy for glioblastoma, a phase I/II evaluation of dual-payload gene therapy to enhance anti-tumor immune responses, and a phase I study employing pH-sensitive MRI techniques to identify infiltrating tumor cells and guide surgical resection. Additional trials explore advanced imaging methodologies to assess the tumor immune microenvironment. Patients interested in enrollment are encouraged to consult the provided trial links and contact responsible parties for eligibility criteria and participation details.

Here, Cedars-Sinai Medical Center discusses crossing the blood–brain barrier (BBB), a defining challenge in the development of effective therapies.

Researchers at Washington University School of Medicine have demonstrated promising results from a personalized cancer vaccine trial for glioblastoma, the most aggressive form of brain cancer. The vaccine, called GNOS-PV01, is customized for each patient using engineered DNA that instructs the immune system to recognize and attack tumor-specific proteins called neoantigens. Unlike conventional chemotherapy, which proves ineffective for certain glioblastoma subtypes, this innovative approach leverages the body's own immune defenses. A clinical trial patient with the most aggressive glioblastoma variant has remained cancer-free for nearly five years following vaccination, suggesting the treatment could provide a viable alternative to traditional surgery and radiation for patients with limited options.

Researchers have demonstrated that long-acting interleukin-7 significantly enhances the therapeutic effectiveness of oncolytic viral therapy for treating glioblastoma, an aggressive brain cancer. This immunological approach leverages the cytokine's ability to strengthen immune response mechanisms, enabling viral therapies to more effectively target and eliminate cancer cells. The combination strategy addresses a critical limitation of conventional oncolytic virus treatments by bolstering anti-tumor immunity. These findings suggest promising potential for improving patient outcomes in glioblastoma management, potentially establishing a new therapeutic paradigm that combines immunomodulation with oncolytic viral agents for enhanced clinical efficacy.